CDER Director's' video advises focusing on the work and "keeping our heads down."
In an acknowledgement that post-election jitters are a significant concern, senior officials at the US FDA are advising members of the rank-and-file to concentrate on their work instead of thinking about potential changes that could be made at the agency by the incoming Trump administration.
Center for Drug Evaluation and Research Director Janet Woodcock made a four- to five-minute video, released internally Dec. 13, that...
Recent studies show that spaceflight can significantly weaken astronauts’ immune systems, making them more susceptible to infections and health complications during and after missions. Understanding these changes is crucial for ensuring the safety of future long-duration space travelers.
Recent ODAC meetings suggest the FDA will expand focus beyond applications with pending approval decisions to refining trial designs and drug labels for competitors.
The US FDA Commissioner pushed for a rebalancing of the US’s pharmaceutical supply chains while also stressing that there is a role for US-China commerce that would be risky to compromise.
Recent ODAC meetings suggest the FDA will expand focus beyond applications with pending approval decisions to refining trial designs and drug labels for competitors.
The US FDA Commissioner pushed for a rebalancing of the US’s pharmaceutical supply chains while also stressing that there is a role for US-China commerce that would be risky to compromise.
